Generali Investments Management Co LLC Boosts Position in Pfizer Inc. $PFE

Generali Investments Management Co LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 128.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,419 shares of the biopharmaceutical company’s stock after buying an additional 31,697 shares during the period. Generali Investments Management Co LLC’s holdings in Pfizer were worth $1,366,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Y.D. More Investments Ltd increased its holdings in shares of Pfizer by 8.0% in the second quarter. Y.D. More Investments Ltd now owns 22,028 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 1,628 shares during the period. Westpac Banking Corp grew its position in Pfizer by 18.6% during the second quarter. Westpac Banking Corp now owns 226,030 shares of the biopharmaceutical company’s stock worth $5,479,000 after buying an additional 35,422 shares in the last quarter. Western Wealth Management LLC raised its holdings in shares of Pfizer by 23.7% in the 2nd quarter. Western Wealth Management LLC now owns 47,071 shares of the biopharmaceutical company’s stock valued at $1,141,000 after acquiring an additional 9,026 shares in the last quarter. Bell Investment Advisors Inc boosted its position in shares of Pfizer by 21.5% during the 2nd quarter. Bell Investment Advisors Inc now owns 4,651 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 823 shares during the last quarter. Finally, Summitry LLC purchased a new position in shares of Pfizer during the second quarter worth about $217,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Price Performance

PFE opened at $25.08 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s 50 day simple moving average is $24.80 and its 200 day simple moving average is $24.45. The firm has a market cap of $142.57 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.